Neurocrine Biosciences

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The firm's product includes INGREZZA. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Neurocrine Biosciences reports strong Q4 performance and eyes growth

Neurocrine Biosciences delivered strong performance in Q4 2022, with robust INGREZZA sales and a positive outlook for 2023, supported by significant investments in SG&A and R&D.
The company's focus on expanding into long-term care, advancing pipeline assets, and collaborations for innovative treatments positions it well for growth and addressing unmet needs.
While facing challenges in managing increased spending and market dynamics, Neurocrine remains optimistic about opportunities in expanding treatment reach, market penetration, and advancing clinical programs.

Neurocrine Biosciences reports strong Q1 performance and eyes international expansion

Neurocrine Biosciences had a strong Q1 performance with record sales, upcoming milestones, and disciplined expense management.
The company faces challenges in certain therapeutic categories but is optimistic about addressing unmet needs and expanding internationally.
Opportunities lie in innovative science, market positioning, and portfolio expansion, positioning Neurocrine for future growth.
Addressing concerns around drug interactions, dosing strategies, and trial risks will be crucial for maintaining clinical success and patient safety.

Neurocrine Biosciences excels in Q2, eyes growth opportunities ahead

Neurocrine Biosciences shows strong financial performance and growth prospects.
Focus on INGREZZA's persistency and pipeline advancements drives optimism.
Challenges include market dynamics and clinical trial complexities.
Opportunities lie in new indications, long-term care expansion, and telemedicine.

Neurocrine Biosciences excels in Q3, eyes growth in LTC segment

Neurocrine Biosciences delivered a strong Q3 performance with robust sales, positive regulatory developments, and promising pipeline advancements.
The company's focus on expanding indications, exploring combination therapies, and addressing market opportunities positions it for future growth.
While facing challenges in market evaluation and competition, Neurocrine Biosciences has opportunities to leverage its strengths and drive innovation.
Investors can look forward to upcoming events like the Analyst Day and R&D Day for deeper insights into the company's strategic direction and growth potential.

Neurocrine Biosciences excels in 2023, eyes Crinecerfont launch success

Neurocrine Biosciences had a strong 2023 with notable achievements in sales growth and pipeline advancements. While facing challenges in market dynamics and pricing negotiations, the company is well-positioned to leverage opportunities in upcoming launches and strategic growth initiatives.

Neurocrine Biosciences excels in Q1 with strong sales and pipeline advancements

Neurocrine Biosciences delivered a strong performance in Q1 2024, driven by robust INGREZZA sales, promising Phase II results for NBI-845, and advancements in Crinecerfont development.
The company's strengths lie in its diverse pipeline, financial stability, and strategic focus on chronic therapy and tolerability, positioning it for future growth and innovation.
While facing challenges in dosing optimization and revenue management, Neurocrine has opportunities to leverage its pipeline, explore new treatments, and differentiate its offerings in the market.

Neurocrine Biosciences excels in Q3, poised for growth ahead

Neurocrine Biosciences showcased robust performance in Q3, with strong INGREZZA sales and pipeline success, positioning for future growth.
The company's strengths lie in its expanded sales team, leadership quality, and commitment to innovation and value creation for shareholders.
Challenges include potential payer reimbursement issues, FDA interactions for Phase III strategy, and competitive pressures in the market.
Opportunities abound with upcoming regulatory approvals, pipeline advancements, and targeted commercial strategies for new product launches.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

BioMarin Pharmaceutical

Catalyst Pharmaceuticals

Vertex Pharmaceuticals

Biotech stocks have swung sharply higher, buoyed by several factors. Could they be poised to lead the market though the next big upturn?

Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin

SAN DIEGO , Sept. 15, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced the presentation of survey findings demonstrating the need for education on supportive evidence regarding best approaches to managing tardive dyskinesia (TD) symptoms while maintaining control of the underlying psychiatric disorder.

Neurocrine Biosciences to Present Study Findings on Evolving Tardive Dyskinesia Education Needs of Physicians at the 2022 MDS International Congress

SAN DIEGO , Sept. 15, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today will present data on the effects of ONGENTYS® (opicapone) capsules on soluble-catechol-O-methyltransferase (S-COMT) enzyme inhibition.

Neurocrine Biosciences Presents New Post-Hoc Analysis of ONGENTYS® (opicapone) Capsules Effect on COMT Activity at the 2022 MDS International Congress

86 percent of people with Parkinson's disease (PD) (n=113) taking the survey experience OFF time daily, and a majority report it has a significant impact on activities While three in four people with PD (78%) report that their current treatment plan is effective at limiting their PD symptoms, over half (56%) also say that they don't think their symptoms can improve beyond their current state SAN DIEGO , Sept. 12, 2022 /PRNewswire/ -- Parkinson & Movement Disorder (PMD) Alliance, in partnership with Neurocrine Biosciences (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company committed to meeting the needs of people with complex and debilitating disorders, today announced results from the Survey Assessment: Impact of OFF Time on People with Parkinson's Disease and Their Care Partners.

Parkinson & Movement Disorder (PMD) Alliance and Neurocrine Biosciences Announce New Survey Results Revealing the Significant Impact OFF Time Has on People with Parkinson's Disease and Their Care Partners

Amazon

Biohaven Pharmaceutical Hld

Salesforce

Dollar General

Alphabet

Healthcare Realty Trust Inc

Eli Lilly

Microsoft

PayPal

Seagen

Snowflake

T-Mobile US

Big investors are famous for breaking rank from the S&P 500 crowd. So when you see a few agreeing on a stock, it's worth paying attention.

15 Stocks Billionaire Investors Agree It's Smart To Buy Now

Axsome Therapeutics

These three biotech companies have bucked the trend of declining shares prices in their sector.

3 Growth Stocks That Are Crushing It This Year

SAN DIEGO , Sept. 6, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Morgan Stanley 20th Annual Global Healthcare Conference at 10:35 a.m.

Neurocrine Biosciences to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

Neurocrine Biosciences leads five medical stocks near key support levels as the health care sector shows resilience in a sickly market. The post Neurocrine Leads 5 Stocks To Watch In Sickly Market appeared first on Investor's Business Daily.

Neurocrine Leads 5 Stocks To Watch In Sickly Market

Neurocrine is acquiring beaten-down Diurnal Group for $57M, primarily to accelerate its ex-U.S. business development. Diurnal has a pipeline of hormone-based therapeutics, including Efmody (commercialized in Europe), but the pipeline is likely secondary to the clinical/commercial infrastructure Diurnal offers.

Neurocrine Biosciences Goes Dumpster-Diving To Accelerate Its International Business Development

Neurocrine saw a meaningful improvement in Ingrezza sales, with revenue growing 32% and beating sell-side expectations by 8%. Management announced that '104 failed to show meaningful efficacy in a Phase II proof-of-concept study, and the company has few near-term clinical catalysts.

Neurocrine Is Seeing A Very Welcome Pick Up In Ingrezza, But Pipeline Catalysts Are Thin

Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Todd Tushla - Vice President of Investor Relations Kevin Gorman - Chief Executive Officer Matt Abernethy - Chief Financial Officer Eiry Roberts - Chief Medical Officer Eric Benevich - Chief Commercial Officer Kyle Gano - Chief Business Development and Strategy Officer Conference Call Participants Phil Nadeau - Cowen & Company Leonid Timashev - RBC Capital Markets Paul Matteis - Stifel Tazeen Ahmad - Bank of America Neena Bitritto-Garg - Citi Jay Olson - Oppenheimer Carter Gould - Barclays Anupam Rama - JPMorgan Brian Skorney - Baird Chris Shibutani - Goldman Sachs Myles Minter - William Blair Danielle Brill - Raymond James Laura Chico - Wedbush Marc Goodman - SVB David Amsellem - Piper Sandler Yatin Suneja - Guggenheim Partners Operator Good day, everyone. And welcome to today's Neurocrine Biosciences Reports Second Quarter Results [Operator Instructions].

Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q2 2022 Results - Earnings Call Transcript

TOKYO and CAMBRIDGE, United Kingdom, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, has been notified by its partner Neurocrine Biosciences Inc. (“Neurocrine”; Nasdaq: NBIX) that the U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) Application for a Phase 2 clinical trial of NBI-1117568 for the treatment of schizophrenia has been accepted by the FDA and that the study may proceed. The achievement of this important clinical development milestone triggers a $30 million payment to Sosei Heptares from Neurocrine.

Sosei Heptares' Oral, Selective M4 Receptor Agonist Advancing into Phase 2 Clinical Development under Multi-Program Collaboration with Neurocrine Biosciences

Neurocrine (NBIX) delivered earnings and revenue surprises of -132.14% and 11.03%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Neurocrine Biosciences (NBIX) Reports Q2 Loss, Tops Revenue Estimates

Neurocrine Biosciences said Thursday its essential tremor study didn't pan out, and it shuttered the program. NBIX stock was flat.

Neurocrine Biosciences Shelves Key Drug; Will It Overshadow The Earnings Beat?

INGREZZA® (valbenazine) Second Quarter Net Product Sales of $350 Million INGREZZA® (valbenazine) 2022 Net Product Sales Guidance Raised to $1.35 - $1.40 Billion Essential Tremor Signal-Seeking Study Did Not Meet Specified Endpoints SAN DIEGO , Aug. 4, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second quarter ended June 30, 2022 and raised net sales guidance for INGREZZA in 2022. "Following INGREZZA's strong performance in the first half of this year, we raised full year net sales guidance.

Neurocrine Biosciences Reports Second Quarter 2022 Financial Results and Raises 2022 INGREZZA Sales Guidance

It's make-or-break time for Neurocrine Biosciences' essential tremors treatment, analysts say, as NBIX stock trends sideways. The post The Make-Or-Break Moment Is Here For Highly Rated Neurocrine Biosciences appeared first on Investor's Business Daily.

The Make-Or-Break Moment Is Here For Highly Rated Neurocrine Biosciences

Assurant

FTI Consulting

Grocery Outlet

Incyte

Coca-Cola

Leidos Hld

The stock market is suffering a turbulent 2022 so far – and with inflation still running at a 40-year high, the Federal Reserve locked in a significant rate-hiking cycle and midterm elections just months away, it's likely the volatility is going to remain for the time being. Investors looking for a smoother market ride should consider buying low-volatility stocks as a way to manage risk.

10 Best Low-Volatility Stocks to Buy Now

Neurocrine should soon release Phase II data on NBI-827104, and a positive read-out on a largely overlooked drug today could add 5% to 10% to NBIX's fair value. Between the expansion of the sales force and new marketing initiatives, Neurocrine is looking to reignite sales momentum in Ingrezza, a drug that I still believe has meaningful growth potential.

Better Ingrezza Sales And A Clinical Trial Read-Out Could Reignite Neurocrine Shares

Conference Call and Webcast Scheduled for Thursday, August 4 SAN DIEGO , July 14, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report second quarter 2022 financial results after the Nasdaq market closes on Thursday, August 4, 2022. Neurocrine will then host a conference call and webcast to discuss its financial results and provide a company update that day at 1:30 p.m.

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2022 Financial Results

- Substantial Reductions in Key Hormones and Hormone Precursors Observed After 14 Days of Crinecerfont Treatment in Adolescents with Classic CAH - Two Phase 3 Global Registrational Studies Currently Underway in Pediatric (2–17 years of age) and Adult (18 years of age and older) Patients with Classic CAH SAN DIEGO , June 13, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present new Phase 2 data on the use of crinecerfont in adolescent patients with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD), which demonstrated substantial reductions in adrenal androgens and androgen precursors. These data will be shared as an oral presentation by Ron S.

Neurocrine Biosciences Presents Data on Treatment of Adolescent Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2022

SAN DIEGO , June 8, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Goldman Sachs 43rd Annual Global Healthcare Conference at 10:40 a.m. Pacific Time (1:40 p.m.

Neurocrine Biosciences to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

SAN DIEGO , June 6, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) was honored by the CARES Foundation for its ongoing research and development of novel therapies for patients with classic congenital adrenal hyperplasia (CAH). The CARES Foundation, Inc. is the only U.S.-based nonprofit organization solely dedicated to improving the lives of the CAH patient community and seeks to advance quality health care.

Neurocrine Biosciences Honored at CARES Foundation 22nd Anniversary Gala

SAN DIEGO , June 6, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presents data on sleep disturbances in Parkinson's disease (PD) demonstrating the impact of OFF episodes, or reemergence of symptoms between doses of levodopa, on falling asleep and staying asleep. These data (abstract ID: 0581) are being shared at SLEEP 2022, the annual meeting of the Associated Professional Sleep Societies, LLC (APSS) being held June 4-8 in Charlotte, North Carolina.

Neurocrine Biosciences Presents Data on Sleep Disturbances and OFF Time in Patients with Parkinson's Disease and Motor Fluctuations at SLEEP 2022

SAN DIEGO , May 24, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) (the "Company" or "Neurocrine Biosciences") today announced that it has entered into separate, privately negotiated transactions (the "Agreements") with certain holders of its existing 2.25% Convertible Senior Notes due 2024 (the "2024 Notes") to repurchase approximately $179.4 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of an amount of cash estimated to be the sum of (i) approximately $224.0 million, (ii) an amount based in part on the trading price of the Company's common stock and (iii) accrued and unpaid interest. The 2024 Notes repurchases are expected to close over a period ending on June 14, 2022, subject to customary closing conditions.

Neurocrine Biosciences Announces Repurchase of Convertible Notes

SAN DIEGO , May 23, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present data on the use of INGREZZA® (valbenazine) capsules for the treatment of tardive dyskinesia (TD) at the American Psychiatric Association (APA) Annual Meeting being held in person May 21-25 in New Orleans and virtually June 7-10. Neurocrine Biosciences, the leading neuroscience-focused company in the treatment of TD, will present findings from a post hoc analysis of two long-term studies of INGREZZA evaluating global TD improvement and stability of psychiatric symptoms (Poster title: Poster #P7-088 Global Improvements and Psychiatric Stability in Adults with Tardive Dyskinesia: Post Hoc Analyses of Two Long-Term Valbenazine Studies).

Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Data on Tardive Dyskinesia Improvement and Stability of Psychiatric Symptoms at American Psychiatric Association Annual Meeting 2022

News for Neurocrine Biosciences Stock (NBIX)